Galux raises $29 million and partners with OliX on AI-based siRNA delivery
Galux completed a $29 million Series B financing and entered an MOU with OliX Pharmaceuticals to jointly develop a next-generation AI-based siRNA delivery platform. The funding will support GaluxDesign, R&D expansion and preclinical validation.
Galux has completed a $29 million (KRW 42 billion) Series B financing, bringing its total capital raised to $47 million (KRW 68 billion), and OliX Pharmaceuticals said it signed a memorandum of understanding with Galux to jointly develop a next-generation AI-based siRNA delivery platform. The agreement will combine Galux’s AI-based delivery design with OliX’s OASIS siRNA platform, with the goal of enabling more precise siRNA therapeutics and supporting future joint research and commercialization.
Based on this partnership, the two companies plan to expand joint research and explore business opportunities. The siRNA therapeutics field has recently been shifting from a liver (hepatic)-centric focus toward extrahepatic tissues. In response, OliX is advancing its “OliX 2.0” strategy by pursuing research into extrahepatic targets and broadening tissue applications using its proprietary OASIS platform.
OliX said it is expanding collaborations to secure delivery technologies, including joint research with firms developing blood-brain barrier (BBB) shuttle technologies for central nervous system targets. Galux has proprietary protein design capabilities based on its GaluxDesign platform. Using AI, Galux can design optimized proteins for specific disease targets from scratch, considering multiple therapeutic properties to identify candidates with high developability.
Galux has developed an AI-driven protein design platform, GaluxDesign, which specialises in de novo antibody design. GaluxDesign successfully generated high-affinity antibodies against a range of therapeutic targets and confirmed that its AI-designed antibody structure was highly consistent with the cryo-EM experimental structure, demonstrating both the precision and generalizability of the platform. The tight integration of pioneering AI with efficient experimental feedback from the company’s internal wet lab is rapidly enhancing the platform’s precision and reliability.
Building on this foundation, the platform is being extended to increasingly challenging target classes, including GPCRs and ion channels. The company has established co-development partnerships with major domestic pharmaceutical companies such as Celltrion and LG Chem, and recently announced a collaboration with Boehringer Ingelheim. Proceeds from the financing round will be used to further enhance its AI platform, expand R&D infrastructure, and accelerate preclinical validation of proprietary pipelines.
Galux previously closed an $18 million (KRW 21 billion) Series A financing in 2022, which enabled the company to advance its AI platform and R&D capabilities. The Series B round brought together existing investors including InterVest, DAYLI Partners, and PATHWAY Investment, alongside new investors including Yuanta Investment, Korea Development Bank, SL Investment, NCORE Ventures, SneakPeek Investments, Korea Investment & Securities, and Mirae Asset Securities.